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ABSTRACT
Introduction: Clostridioides difficile (C. difficile) infection (CDI) is one of the most common
healthcare-associated (HA) infections in contemporary medicine. The risk factors (RFs) for HA
CDI in medical and surgical patients are poorly investigated in countries with a limited
resource healthcare system. Therefore, the aim of the study was to investigate differences
in patients’ characteristics, factors related to healthcare and outcomes associated with HA CDI
in surgical and medical patients in tertiary healthcare centre in Serbia.
Materials and Methods: A prospective cohort study was conducted including adult patients
diagnosed with initial episode of HA CDI, first recurrence of disease, readmission to hospital,
while deaths within 30 days of CDI diagnosis and in-hospital mortality were also recorded.
Patients hospitalized for any non-surgical illness, who developed initial HA CDI were assigned
to medical group, whereas those who developed initial HA CDI after surgical procedures were
in surgical group. The data on patients’ characteristics and factors related to healthcare were
collected, too.
Results: During 7-year period, from 553 patients undergoing in-hospital treatment and
diagnosed with CDI, 268 (48.5%) and 285 (51.5%) were surgical and medical patients,
respectively. Age ≥ 65 years, use of proton pump inhibitors, chemotherapy and fluoroquino-
lones were positively associated with being in medical group, whereas admission to intensive
care unit and use of second- and third-generation cephalosporins were positively associated
with being in surgical group.
Conclusions: Based on obtained results, including significant differences in 30-day mortality
and in-hospital mortality, it can be concluded that medical patient were more endangered
with HA CDI than surgical ones.
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1. Introduction
Clostridioides difficile (C. difficile) infection (CDI) became
one of the most common healthcare-associated (HA)
infections in modern medicine. It is associated with the
increased morbidity, in-hospital mortality, prolonged
hospitalization, and increased costs [1]. The reported
incidence of HA CDI varies according to the country,
the size of institution and ward location, the type of
population studied [2–4]. Several studies conducted in
industrialized countries of North America, Europe, and
Western Pacific region, synthesized in different systema-
tic review, provide valuable insights into the role of
different risk factors (RFs) for CDI. Meta–analytic evi-
dence of association has been reported for factors
such as antibiotics, gastric acid suppressants, non–selec-
tive steroid anti-inflammatory drugs (NSAIDs), and some
co–morbidities [5,6]. Systematic review of existing litera-
ture describing the epidemiology and management of
CDI in developing countries showed that the rate of
community-associated (CA) and HA CDI appears to be
lower in developing countries than in developed coun-
tries, yet RFs appear to be broadly similar between these
two populations. Accordingly, the future epidemiologi-
cal studies in developing countries describing basic
epidemiology of CDI, RFs for development of CDI,
patient morbidity and mortality, as well as financial
burden of infection are urgently needed [7].
The differences in RFs for HA CDI between medical
and surgical patients are also poorly investigated in
countries with socioeconomic transition with a limited
resource healthcare system. Some studies from well-
developed healthcare systems provided evidence that
although surgical patients tend to suffer more severe
CDIs than medical patients, overall they still do better
than medical ones [8]. Southern et al. showed that in
comparison with medical patients with CDI, surgical
patients with CDI were significantly less likely to have
had a prior hospitalization, less likely to have received
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a proton-pump inhibitors (PPIs) and more likely to
have received antibiotics [9].
The aim of this study was to investigate differences
in patients’ characteristics, factors related to health-
care and outcomes in surgical and medical patients
with HA CDI in tertiary healthcare centre in Serbia.
2. Materials and methods
2.1. Study design, patients and definitions
A prospective cohort study was conducted including
adult patients (≥ 18 years) diagnosed with initial episode
of HA CDI from 1 January 2011 to 31 December 2017 at
the Military Medical Academy (MMA), Belgrade (Serbia),
a 1200-bed teaching hospital of theUniversity ofDefence.
The hospital is divided into 27 departments. In our tertiary
healthcare centre positive testing for CDI is immediately
reported to infectious diseases specialist and healthcare
epidemiologist. Infectious diseases specialist evaluates
best treatment options (metronidazole or vancomycin
or combination of both antibiotics). Healthcare epide-
miologist evaluates origin, patients’ characteristics, factors
related to healthcare and outcomes of infection. Infection
control nurse recommends CDI control measures. CDI
control measures: includes contact isolation, personal
safety equipment at patient contact, extensive hand-
washing with soap and water, and daily disinfection of
a patient room with sporicidal agent.
We gathered data on the following variables:
intrinsic factors (existing at admission) sex, age,
Diabetes mellitus, malignancy, and factors related to
healthcare, including previous hospitalization in other
hospitals, previous infections, intensive care unit (ICU)
admission, duration of treatment in ICU, mechanical
ventilation (MV), nasogastric tubes (NT), use of hista-
mine-2-receptor antagonists (H2RAs), PPIs, che-
motherapy and antibiotics (number, type, and
duration of antibiotic usage). Data about the length
of stay (LOS) in hospital, first recurrence of CDI, read-
mission to MMA, deaths within 30 days of CDI diag-
nosis and in-hospital mortality were also recorded.
HA CDI case was defined as any hospitalized patient
with laboratory confirmation of a positive toxin assay of
C. difficile associatedwith diarrhoea (≥ 3 daily in a 24-hour
periodwith no other recognized cause) or visualization of
pseudomembranes on sigmoidoscopy, colonoscopy, or
histopathologic analysis on day three or later, following
admission to an MMA on day one [10–12]. We also
included all patients readmitted to MMA. Readmission
to MMA was defined as readmitted patients who did
not have a CDI during their index admission to hospital,
but had onset of symptoms within four weeks of dis-
charge from MMA [13]. Microbiological testing was per-
formed at the Institute of Medical Microbiology at the
MMA. Enzyme immunoassay kits for C. difficile toxins
A and B were used (BIOMERIEUX- VIDAS C. difficile toxins
A&B CDAB).
First CDI recurrence was defined as return of symp-
toms associated with repeated positive test within
15–56 days after the initial diagnosis was established
[10]. Patients with CA CDI and HA CDI acquired in
another hospital were excluded from study.
Patients hospitalized for any non-surgical illness,
who developed initial HA CDI were assigned to med-
ical group, whereas those who developed initial HA
CDI after surgical procedures were assigned to
a surgical group. The Ethics Committee of the MMA
approved the research protocol (MF VMA 02/17-19).
2.2. Statistical analysis
Data analyses were performed with SPSS, version 21.0
(SPSS, Chicago, IL). Results were expressed as the
mean ± SD or as the proportion of the total number
of patients. The χ2 test or Fischer exact test were used
for categorical variables and relative risk, and their
corresponding 95% confidence intervals (CI) were cal-
culated. For parametric continuous variables, mean
values were compared using the Student t test. For
nonparametric continuous variables the Mann-
Whitney U test was used. RF independently associated
with CDI were identified by stepwise logistic regres-
sion analysis of variables selected by univariable logis-
tic regression analysis (ULRA), with a limit for entering
and removing categorical variables from the model at
0.05. The in-hospital mortality rate was defined as the
number of deaths per 100 patients with HA CDI. The
30-day mortality was defined as death within 30 days
after the diagnosis of HA CDI per 100 patients with
HA CDI.
3. Results
During 7 years we registered 836 patients with labora-
tory proven CDI. Among them, 183 patients acquired
infection in community or in another hospital, and
were not included in study. There were 553 patients
undergoing in-hospital treatment at MMA who devel-
oped initial HA CDI and were included in the study.
No major CDI outbreaks were observed during the
study period.
More detailed characteristics of patients and fac-
tors related to healthcare are shown in Table 1. Of
these, 268 (48.5%) and 285 (51.5%) were surgical and
medical patients, respectively.
There were 251 female patients, 123 (45.9%) surgi-
cal and 128 (44.9%) medical, without significant dif-
ferences between cohorts according to gender.
Medical patients were significantly older than surgical
(68.59 ± 15.46 vs. 64.91 ± 14.86, respectively;
p = 0.005). We observed that both, medical and
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surgical patients, had similar distribution of Diabetes
mellitus (17.9% vs 13.8%, respectively, p = 0.231) and
malignancy (23.2% vs. 23.5%, respectively, p = 1.000)
without significant differences between them.
Previous infection and previous hospital admission
were significantly more frequent in medical than in
surgical patients (44.9% vs. 36.2%; p = 0.037 and
52.3% vs. 38.4%; p = 0.001, respectively). There were
no differences according to the season of HA CDI
between cohorts (p = 0.524).
ICU stay was registered significantly more fre-
quently in surgical patients (35.4% vs. 10.9%,
p < 0.001), while the LOS in ICU was significantly
longer in medical patients (25.23 ± 33.97 vs.
7.16 ± 12.09, p < 0.001). There were no differences
in frequency of use of NT and MV between surgical
and medical patients (10.4% vs. 11.2%, p = 0.874 and
14.6% vs. 15.4%, p = 0.863, respectively). There were
no differences in frequency of H2RAs use (40.7% vs.
38.9%, p = 0.744), but medical patients were treated
significantly more frequently with PPIs than surgical
patients (38.9% vs. 19.0%, respectively, p < 0.001).
Chemotherapy was also significantly more frequently
administered to medical than to surgical patients
(12.6% vs. 1.9%, respectively, p < 0.001).
Antibiotic exposure was registered more frequently
in surgical than in medical patients (98.1% vs. 91.9%,
respectively, p < 0.001), but duration of antibiotic
treatment, in days, was significantly longer in medical
patients than in surgical ones (8.63 ± 5.60 vs.
6.59 ± 4.79, respectively, p < 0.001). In comparison
with medical patients, surgical patients were signifi-
cantly more often administered second-generation
cephalosporins (17.6% vs. 30.0%, respectively,
p = 0.001) and third-generation cephalosporins
(53.1% vs. 64.6% respectively, p = 0.007), while med-
ical patients received more often fluoroquinolones in
comparison to surgical patients (28.6% vs. 9.9%,
respectively, p < 0.001). More detailed characteristics
of patients, factors related to healthcare itself, and
results of ULRA and multivariate logistic regression
analysis (MLRA) are shown in Table 1.
Table 1. Comparison of patients’ characteristics and factors related to healthcare in surgical and medical patients with HA CDI.
Surgical patients N = 268 Medical patients N = 285 Crude RR* ULRA* P MLRA* RR (95%CI) MLRA p
Patients characteristic
Female sex, n (%) 123 (45.9) 128 (44.9) 0.883
Age, X ± SD 64.91 ± 14.86 68.59 ± 15.46 0.005
Age ≥ 65 years, n (%) 154 (57.5) 190 (66.7) 1.481 0.026 2.015 (1.347–3.014) 0.001
Diabetes mellitus, n (%) 37 (13.8) 51 (17.9) 0.231
Malignancy, n (%) 63 (23.5) 66 (23.2) 1.000
Previous infection, n (%) 97 (36.2) 128 (44.9) 1.437 0.037
Factors related to healthcare
Season of CDI infection
Spring
Summer
Autumn
Winter
78 (29.1)
59 (22.0)
65 (24.3)
66 (24.6)
95 (33.3)
66 (23.2)
56 (19.6)
68 (23.9)
0.524
Previous hospital admission 103 (38.4) 149 (52.3) 1.755 0.001
ICU*admission, n (%) 95 (35.4) 31 (10.9) 4.499 <0.001 4.730 (2.877–7.775) <0.001
Length of stay in ICU, (days), X ± SD 7.16 ± 12.09 25.23 ± 33.97 <0.001
Nasogastric tube, n (%) 28 (10.4) 32 (11.2) 0.874
Mechanical ventilation, n (%) 39 (14.6) 44 (15.4) 0.863
Days of hospitalization prior CDI, X± SD 21.22 ± 18.68 17.79 ± 17.48 0.004
Proton-pump inhibitors, n (%) 51 (19.0) 111 (38.9) 2.714 <0.001 3.431 (2.188–5.379) <0.001
H2 receptor antagonist, n (%) 109 (40.7) 111 (38.9) 0.744
Chemotherapy, n (%) 5 (1.9) 36 (12.6) 7.605 <0.001 4.708 (1.718–12.906) 0.003
Antibiotic exposure, n (%) 263 (98.1) 262 (91.9) 4.618 <0.001
Number of received antibiotics
One
Two
Three
Four
118 (44.9)
66 (25.1)
41 (15.6)
38 (14.4)
102 (38.9)
79 (30.2)
50 (19.1)
31 (11.8)
0.269
Days of usage an antibiotic (X± SD) 6.59 ± 4.79 8.63 ± 5.60 <0.001
Days of usage two antibiotics (X± SD) 7.50 ± 5.06 7.83 ± 5.46 0.519
Days of usage three antibiotics (X± SD) 7.62 ± 5.89 7.43 ± 4.23 0.656
Days of usage four antibiotics (X± SD) 8.45 ± 4.05 8.58 ± 4.79 0.995
Cephalosporins 1st gen, n (%) 24 (9.1) 17 (6.5) 0.335
Cephalosporins 2nd gen, n (%) 79 (30.0) 46 (17.6) 2.016 0.001 1.924 (1.177–3.145) 0.009
Cephalosporins 3rd gen, n (%) 170 (64.6) 139 (53.1) 1.618 0.007 2.173 (1.421–3.322) <0.001
Cephalosporins 4th gen, n (%) 1 (0.4) 4 (1.5) 0.216
Aminoglycosides, n (%) 45 (17.1) 44 (16.8) 1.000
Fluoroquinolones, n (%) 26 (9.9) 75 (28.6) 3.656 <0.001 3.025 (1.751–5.226) <0.001
Sulfonamides, n (%) 19 (7.2) 24 (9.2) 0.516
Carbapenems, n (%) 53 (20.2) 63 (24.0) 0.332
Macrolides, n (%) 5 (1.9) 14 (5.3) 0.060
Clindamycin, n (%) 7 (2.7) 2 (0.8) 0.176
Tigecyclin, n (%) 1 (0.4) 1 (0.4) 1.000
Fosfomycin, n (%) 0 (0) 2 (0.8) 0.249
Colistin, n (%) 4 (1.5) 2 (0.8) 0.686
*ICU, intensive care unit; *ULRA, univariable logistic regression analysis; *MLRA, multivariable logistic regression analysis; *RR, relative risk
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MLRA was used to control for confounding vari-
ables. Age ≥ 65 years, use of PPIs, chemotherapy and
fluoroquinolones were positively associated with
being in medical group, whereas admission to ICU
and use of second- and third-generation cephalospor-
ins were positively associated with being in surgical
group.
When we analysed outcomes of HA CDI (Table 2),
there were no significant differences between surgical
and medical patients taking into account the LOS in
hospital (39.93 ± 30.64 vs. 36.49 ± 28.80, respectively,
p = 0.262), frequency of recurrent HA CDI (8.2% vs.
6.0%, respectively, p = 0.388), and readmission to
MMA (5.2% vs. 4.6%, respectively, p = 0.718).
There were significant differences between them in
30-day mortality (15.7% vs. 25.6%, p = 0.006) and in-
hospital mortality (19.8% vs. 28.1%, p = 0.029)
(Table 2).
4. Discussion
We found a number of studies conducted in health
care systems of developed countries regarding epide-
miology, clinical features, and outcomes of HA CDI in
the available literature [2,3,8,9]. The present one pro-
vides important data on patient characteristics, factors
related to health care as well as outcomes in patients
with HA CDI in large cohort of patients admitted to
tertiary care centre in Southeast Europe. Study also
provides further information about epidemiological
differences between HA CDI in medical and surgical
patients in health care system of Serbia as developing
country.
4.1. Medical patients
We found that age ≥ 65 years, use of PPIs, chemother-
apy and fluoroquinolones were positively associated
with medical group and could be significant predic-
tors of CDI in medical patients compared with surgical
patients.
Advance age is frequently cited as one of the
primary RF for CDI. Olsen et al. demonstrated that
age did not improve CDI risk prediction after control-
ling for a wide variety of infections, other acute con-
ditions, frailty indicators, and prior healthcare
utilization [14]. Silva-Velazco et al. showed that surgi-
cal patients were significantly older than medical
patients with HA CDI (60.4 ± 18.2 vs. 57.2 ± 20.4,
respectively) [8]. On the contrary, our medical patients
were significantly older than surgical ones
(68.59 ± 15.46 vs. 64.91 ± 14.86; respectively,
p = 0.005). MLRA in our study also showed that age
≥ 65 years were more frequent among medical than
surgical patients with HA CDI (RR: 2.015; 95% CI: 1.-
347–3.014; p = 0.001).
Since their release in the late 1980s, PPIs have
become some of the most widely prescribed agents
both in outpatient and inpatient settings throughout
the world [15]. Craig et al. conducted large prospec-
tive observational study and concluded that the
majority of intravenous PPI prescriptions within hos-
pital practice were inappropriate [16]. With a wide
range of prescription practices, the undesirable effects
of these drugs have also been reported. Meta-analysis
which included the largest number of observational
studies published to date found that the risk of CDI
was almost two-times higher in PPIs users than in
nonusers [6]. In our study MLRA determined that the
use of PPI was positively associated with CDI in the
medical patients compared with the surgical cohort
(RR: 3.431; 95% CI: 2.188–5.379; p < 0.001). This result
is not surprising and is similar to that reported by
Southern and colleagues [9]. Yet, in the last update
of recommendations of the clinical practice guidelines
for CDI in adults and children by the Infectious
Diseases Society of America (IDSA) and Society for
Healthcare Epidemiology of America (SHEA) there is
the state that ‘Although there is an epidemiologic
association between PPI use and CDI, and unneces-
sary PPIs should always be discontinued, there is
insufficient evidence for discontinuation of PPIs as
a measure for preventing CDI’ [12].
An association between the chemotherapy use and
CDI has already been reported in previous studies
[17,18]. On the contrary, Fuereder et al. demonstrated
that chemotherapy per se is not a RF for CDI in
hemato-oncological patients. They concluded that
antimicrobial therapy was a major RF observed inde-
pendently from chemotherapy in the examined
cohort [19]. Oncology patients are at a high risk of
CDI, in keeping with the frequency of known RF in
that population: chemotherapy, antibiotic use, prior
and prolonged hospitalizations, use of feeding tubes,
use of PPIs, etc. In our study the chemotherapy was
significantly more frequently administered to medical
than surgical patients (12.6% vs 1.9%, respectively,
p < 0.001) and this significance did retain in MLRA.
According to patients’ risk of developing CDI, cepha-
losporins, carbapenems, fluoroquinolones and clinda-
mycin were in the group of high-risk antibiotics [20].
Our results showed that previous infection was more
frequent in medical patients than in surgical patients
Table 2. Outcomes in surgical and medical patients with
Clostridioides difficile Infections (CDI).
Surgical patients
N = 268
Medical patients
N = 285 p
Length of stay in hospital,
(days), X ± SD
39.93 ± 30.64 36.49 ± 28.80 0.262
In hospital mortality,
n (%)
53 (19.8) 80 (28.1) 0.029
30-day mortality, p < (%) 42 (15.7) 73 (25.6) 0.006
Recurrent CDI, p < (%) 22 (8.2) 17 (6.0) 0.388
Readmission to MMA* 14 (5.2) 13 (4.6) 0.718
*MMA, Military Medical Academy
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(44.9% vs. 36.2%, respectively, p = 0.037). That could
explain why the use of fluoroquinolones was signifi-
cantly higher in medical group of patients than in
surgical group (28.6% vs 9.9%, respectively, p < 0.001).
CDI and in particular infections caused by the virulent
strain referred to as the North Pulsed Field type 1
(NAP1) and PCR ribotype 027 (NAP-1/027) strain were
known complications of fluoroquinolones treatment
[21]. In the early 2000s, a previously uncommon
C. difficile strain NAP1/027 acquired increased resistance
to fluoroquinolone antibiotics and caused large out-
breaks in North America and Northern Europe [11,22].
Kurti et al. reported an epidemic of CDI with incidence
of 12.6% in a tertiary academic centre in Eastern Europe
between 2010 and 2013. One of the RF for CDI was
antibiotic therapy, including third-generation cephalos-
porins or fluoroquinolones (p < 0.001) [23]. In tertiary
care hospital in Portugal CDI incidence achieved a peak
in 2009/2010 coinciding with the increase in quinolone
and carbapenem prescriptions as well as introduction
of alcohol-based hand products [24]. Although many
countries continued to have high rates of CDI, England
achieved to decrease CDI with fluoroquinolone restric-
tion [25].
A recent systematic review followed by a meta-
analysis regarding HA CDI exhibited increased risks for
this infection after use of several antimicrobial classes
[26]. Among them, fluoroquinolones imposed lower risk
than other classes of antibiotics: third-generation cepha-
losporins, clindamycin, second-generation cephalospor-
ins, fourth-generation cephalosporins, carbapenems
and trimethoprim/sulphonamides [26]. In the study con-
cerning antibiotic consumption and HA infections con-
ducted in our hospital from 2011 to 2016, we did not
find a correlation between fluoroquinolones consump-
tion and incidence density of CDI, but consumption of
fluoroquinolones was very low and varied from 1.7% to
5.4% of total consumption of antibiotics in that period
[27]. However, more rational prescribing process of
fluoroquinolones is not only important due to HA CDI,
but also due to disabling and potentially permanent
side effects which already lead to their suspensions or
restrictions by European Medicines Agency safety com-
mittee (PRAC) in 2018 [28].
4.2. Surgical patients
We found that ICU stay and use of second- and third-
generation cephalosporins were positively associated
with surgical group and could be significant predic-
tors of CDI in surgical patients compared with medical
ones.
Diarrhoea is one of the most common symptoms in
ICU patients. Many factors may cause diarrhoea in
critically ill, including non-infectious (drugs, enteral
feeding, etc.) and infectious (C. difficile and other
bacteria, viruses etc.). According to data from Europe
and North America, reported incidence of HA CDI in
ICU was in the range from 8.7 in Spain [29] to 53.9
cases per 10 000 patient days in US [30]. Our previous
data demonstrated that ICU stay were significantly
associated with HA CDI in surgical patients [4]. We
also observed the differences in incidence density of
HA CDI in medical and surgical patients [27]. In the
current study, there were significant differences in ICU
admission and LOS in ICU between medical and sur-
gical patients (p < 0.001 concerning both variables).
Surgical patients were treated more often than med-
ical in ICU, but medical patients were longer treated
there (25.23 ± 33.97 vs. 7.16 ± 12.09, p < 0.001). Since
only the categorical variables that were statistically
significant in ULRA were also included in our MLRА,
ICU admission was positively associated with CDI in
surgical patients compared with medical patients (RR:
4.730; 95% CI: 2.877–7.775; p < 0.001). Similarly,
Watkinson et al. reported that longer ICU stay was
positively associated with CDI in trauma/surgery
patients compared with medical patients [31].
MV is one of the most common interventions
implemented in ICU. Study from Taiwan’s National
Intensive Care Unit Data base conducted in the large
cohort of intubated patients showed that prolonged
MV (> 21 days) and prolonged carbapenems therapy
(> 15 days) were independent predictors of HA CDI
[32]. In our study there were no differences in fre-
quency of MV use between surgical and medical
patients (14.6% vs. 15.4%, respectively, p =-
0.863). Second-generation cephalosporins were used
more frequently in our surgical than in medical
patients (30.0% vs 17.6%, respectively, p = 0.001)
and this significance was verified in MLRA (RR: 1.924;
95% CI: 1.177–3.145; p = 0.009). Similar data were
registered in the use of third-generation cephalospor-
ins (64.6% vs 53.1%; RR: 2.173; 95% CI: 1.421–3.322,
p < 0.001).
Slimings and Riley found that third-generation
cephalosporins (e.g. cefotaxime) showed increased
risk for HA CDI (OR: 3.20, 95% CI: 1.80–5.71) and that
the second-generation cephalosporins had lower risk
than the third-generation (OR: 2.23, 95% CI: 1.47–3.37)
[26]. The consumption of the third-generation cepha-
losporins (ceftriaxone and ceftazidime) was 66.8% of
all cephalosporins used in our hospital from 2011 to
2016 and surgical antimicrobial prophylaxis was one
of the reasons for these findings [27]. Southern et al.
also found that risk for developing post-surgical CDI
was increased with exposure to pre-operative antibio-
tics, especially the third-generation cephalosporins
and concluded that unnecessary use of antibiotics
before surgery should be avoided [9]. Since, according
to our National Guidelines of Good Clinical Practice
for Rational Usage of Antibiotics [33], only first
and second generation of cephalosporins should be
used for surgical antimicrobial prophylaxis, our
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multidisciplinary hospital healthcare team will con-
tinue to make further efforts in the implementation
of the antibiotic stewardship program as a whole in
order to decrease unnecessary exposures of patients
to antimicrobial agents [27].
4.3. Outcomes
Study of CDI burden following digestive tract surgery
in Japan showed that increased LOS is both a RF for
CDI and its outcomes [34]. Authors Honda et al.
reported a median LOS among 126 CDI cases of
41.5 days (17.5 days before and 18 days post-CDI
diagnosis) [35]. In the USA, patients with HA CDI,
compared with controls, had significantly longer
total LOS (mean ± SD: 14.4 ± 18.3; median (IQ
range) 10 (5–17) vs. mean ± SD: 8.7 ± 15.6, median
(IQ range) 6 (3–10)) [36].
In our study, there were no differences between
surgical and medical patients in total LOS
(39.93 ± 30.64 vs. 36.49 ± 28.80, p = 0.262), but
surgical patients had statistically longer hospitaliza-
tion prior CDI (21.22 ± 18.68 vs 17.79 ± 17.48,
p = 0.004). Silva-Velazco et al. also reported statisti-
cally longer hospitalization prior CDI in surgical
patients [8]. National statistics from Serbia shows
that mean LOS for all eligible patients decreased
from 8.3 in 2013 to 7.3 in 2017 in tertiary healthcare
centres [37]. Based on all of the above, it could be
concluded that CDI in our hospital was HA infection in
long-standing patients, whether they were medical or
surgical.
Hungarian study reported 30-day mortality rate of
21.9% in CDI patients treated in an academic centre in
Eastern Europe [23]. In our experience, the prognosis
of CDI was poorer in medical than in surgical patients,
what was substantiated by the higher 30-day mortal-
ity rate observed in medical patients (25.6% vs. 15.7%,
respectively, p = 0.006). It is higher than it was
reported in Cleveland Clinic in Ohio concerning both
categories of patients (9.9% in medical vs. 6.9% in
surgical patients, p = 0.003) [8]. This difference is
explained by the different levels of healthcare and
treatment of patients in hospitals in Serbia and the
USA. Similar differences were found regarding in-
hospital mortality between medical and surgical
cohorts (28.1% vs 19.8%, respectively, p = 0.029) in
our survey. The research of Watkins and colleagues is
in accordance with our results since the overall survi-
val rate was significantly higher in the trauma/surgery
group than in the medical group (100% vs. 81%,
respectively, p = 0.003) [31]. The study of Oake et al.
showed that HA CDI was independently associated
with an increased risk of in-hospital death and that
across all baseline risk strata, for every 10 patients
acquiring the infection, one person died [38].
Disease recurrence is observed in 15–35% of
patients after an initial episode of CDI, with the rate
rising to 35–65% after the first recurrence [39].
National retrospective cohort study of the burden of
CDI among adult veterans in the USA conducted dur-
ing 11- year period, documented increases in CDI
initial and recurrent episodes [40]. Overall 5011
patients or 17% of the total CDI cohort experienced
first recurrence over the study period. In our survey,
first CD recurrence was detected in 8.2% of surgical
patients and 6.0% of medical patients, without signif-
icant differences between groups (p = 0.388). On the
contrary, Silva-Velazco et al. registered statistically
higher rate of first recurrence in medical than in sur-
gical patients (8.1% vs. 6.3%, p = 0.07) [8].
5. Limitations and strengths of study
First, it is single centre study and our data may not be
generalized to other healthcare centres. Second one is
connected with the fact that although patients from
all MMA departments were included for the surveil-
lance of HA CDI, we had no surveillance of patients
after discharge from the hospital. Therefore, the fre-
quency and impact of postdischarge CDI, initial and
recurrent, could be widely underestimated. Important
limitation of this study was the fact that CDI testing
was based on toxin A/B enzyme immunoassay (EIA) as
the only diagnostic procedure in laboratory (no EIA
detecting glutamate dehydrogenase, no isolation of
C. difficile and detection of toxigenic isolates, no
nucleic acid amplification tests). This procedure has
shown poor sensitivity of less than 50% in studies of
Shin [41] and Swindells [42]. In addition, the meta-
analysis of Crobach et al. showed that no single test
can be used as a stand-alone test for diagnosed CDI
as a result of inadequate positive predictive values at
low CDI prevalence [43]. Another major limitation was
the lack of culture and molecular typing data.
However, the strengths of our study include its
prospective cohort design, 7 years of duration, as
well as ULRA and MLRA strengthened evidence.
6. Conclusions
From our 7-year long cohort study it can be con-
cluded that age ≥ 65 years, use of PPIs, chemotherapy
and fluoroquinolones were positively associated with
medical group and could be significant predictors of
CDI in medical patients compared with surgical
patients. Conversely, ICU stay and use of second-
and third-generation cephalosporins, were positively
associated with surgical group and could be signifi-
cant predictors of CDI in surgical patients compared
with medical ones.
Based on all obtained results, including significant
differences in 30-day mortality and in-hospital
6 V. ŠULJAGIĆ ET AL.
mortality and all limitations of the study, it can be
concluded that medical patients were more endan-
gered with HA CDI than surgical ones. We believe that
our findings could be useful not only for clinicians,
but also for the management of the hospitals in
countries in socioeconomic transition and with
a limited resource healthcare system.
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